Day: September 13, 2021

Tomorrow, 14 September 2021, Pandora will host its online Capital Markets Day, starting at 13.00 CEST. The event will run for approximately four hours. The Executive Leadership Team will present how Pandora will drive long-term sustainable and profitable growth, building on the vast untapped opportunities within the company’s existing business. Presentation materials will be available on the website below from approximately 09.00 CEST on 14 September.   Live stream A link to the live streaming of the event can be accessed via Pandora’s website: https://pandoragroup.com/investor/capital-markets-day-2021   Q&A sessionIt will be possible to ask questions at the end of the event. If you wish to ask a question, please dial in using one of the below phone numbers. The Q&A session will begin at approximately 15.45 CEST, and the lines...

Accomplished MedTech Leader with Proven Track Record of Strategic, Operational and Financial Execution with High Growth Companies SAN FRANCISCO, Sept. 13, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Quentin Blackford has been appointed President and Chief Executive Officer of iRhythm and a member of the Board of Directors (the “Board”), effective October 4, 2021. Mr. Blackford is an accomplished industry leader, bringing more than 20 years of experience scaling premier innovative medical device and digital health companies, including most recently as Chief Operating Officer of Dexcom, Inc., a leader of diabetes care technology. In that role, he was responsible for global operations,...

HUDSON, Ohio, Sept. 13, 2021 (GLOBE NEWSWIRE) — JOANN Inc., the nation’s category leader in sewing and fabrics and one of the fastest growing players in the arts and crafts industry, today announced that its Board of Directors has authorized the Company to repurchase outstanding shares of its common stock. The authorization enables the Company to repurchase up to an aggregate of $20.0 million of the Company’s common stock through open-market transactions, privately negotiated transactions, including through accelerated share repurchases or pursuant to the terms of a Rule 10b5-1 plan, or other transactions. The actual number of shares repurchased will depend on timing, market conditions and other factors, and will be at management’s discretion. The Company is not obligated to make any purchases, and the program may be suspended...

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15pm Eastern Time. To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. About TRACON TRACON...

ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that ONS-5010 ophthalmic bevacizumab, under evaluation for the treatment of wet AMD, showed no unexpected safety trends and had a safety profile consistent with that of prior published data undertaken by the National Eye Institute (2011 CATT trial). “ONS-5010 has the potential to close the gap on a high unmet need for patients...